Upsized

WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics (Nasdaq: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for the treatment of serious and rare diseases, today announced the…

The initial purchasers of the notes are granted an option to purchase, for settlement within a period of 13 days from, and including the date the notes are first issued, up to an additional $55.0 million aggregate principal amount of the…

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire…